Another collaboration for Belgian biotech Confo Therapeutics

3 July 2019

Belgium’s Confo Therapeutics has signed a drug discovery deal with Dresden, Germany-based DyNAbind, focused on an undisclosed G-protein coupled receptor (GPCR).

Confo, which was founded as a spin-off from VIB and Vrije Universiteit Brussel, has raised over 36.7 million euros ($42 million) from an international investor syndicate since it was founded in 2015.

The firm has previously entered into collaborations with Danish CNS specialist Lundbeck (LUN: CO) and with Swiss pharma giant Roche (ROG: SIX), the latter of which was focused on a GPCR for the treatment of neurological and developmental disorders.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK